According to a new report, published by KBV research, The Global Cancer Biomarkers Market size is expected to reach $34.3 billion by 2028, rising at a Market growth of 16.8% CAGR during the forecast period.
The Omics Technologies segment acquired maximum revenue share in the Global Cancer Biomarkers Market by Profiling Technologies in 2021, thereby, achieving a Market value of $11.7 billion by 2028. The growth of this Market is being driven by rising cancer incidence worldwide and increased R&D on cancer biomarkers. Omics technologies give scientists the tools they require to investigate changes in RNA, DNA, proteins, and other biological components between species and between people within a species. These molecular profiles can change in response to chemical or drug exposure in cells or tissues, and so have the potential to be used in toxicological assessments.
The Prognostics segment is showcasing a CAGR of 17.1% during (2022 - 2028). This is due to the fact that it is used to determine the stage and severity of cancer. Prognostics assess the level of a system's deviation or degradation from its predicted normal operating conditions in order to forecast future performance. Prognostics is a science that involves analyzing failure mechanisms, detecting early symptoms of wear and ageing, and determining fault conditions. When there is a solid understanding of the failure processes that are likely to produce degradations and eventually system failures, an effective prognostics solution may be deployed
The Protein segment is leading the Global Cancer Biomarkers Market by Type in 2021, thereby, achieving a Market value of $15.5 billion by 2028. Conventionally, tumor markers have been proteins or other chemicals produced in greater quantities by cancer cells than by normal cells. Some cancer patients' blood, urine, stool, tumours, or other tissues or body fluids contain these substances.
The Colorectal Cancer segment has shown growth rate of 17.3% during (2022 - 2028). The main reason of cancer-related death around the world. CRC has a poor prognosis, and novel diagnostic and prognostic biomarkers are urgently needed to prevent CRC-related deaths. Colorectal cancer biomarkers are utilized in the progression, diagnosis, prognosis, and treatment of the disease. Some biomarkers are prognostic as well as predictive.
The North America is the fastest growing region in the Global Cancer Biomarkers Market by Region in 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $12.0 billion by 2028. The Europe Market is estimated to witness a CAGR of 16.1% during (2022 - 2028). Additionally, The Asia Pacific Market would exhibit a CAGR of 17.8% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/cancer-biomarkers-market/
The Market research report has exhaustive quantitative insights providing a clear picture of the Market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the Market have been discussed in the report with the elaborated company profiles of BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Agilent Technologies, Inc., and Merck & Co., Inc.
By Profiling Technologies
By Application
By Type
By Cancer Type
By Geography
Companies Profiled
Unique Offerings 
